Increased health complications and decreased ability to work or perform daily activities
$34,508–$56,000—estimated cost per bloodstream infection2,3
An estimated 30,000 patient deaths annually attributed to CRBSIs4
An estimated 12%-25% of patients who get a CRBSI will die1
Remunerative or punitive measures for “Never Events"
Healthcare costs associated with treatment will likely exceed $2 billion this year4
Financial and emotional stress as a result of the death of a family member
Diminished reputation of the facility/system and stigma of public reporting of CRBSIs
Increased costs for insurance and medical services
3M™ Tegaderm™ CHG Dressings are the only transparent IV site dressings integrated with a CHG gel pad proven to reduce skin flora,† a leading cause of costly, non-reimbursed CRBSIs.*
In the last three decades, the number of bloodstream infections has nearly tripled in the U.S., with central venous catheters (CVCs) accounting for up to 90% of all catheter-related bloodstream infections (CRBSIs).5 CRBSIs are one of the most costly and deadly infections transmitted in healthcare facilities. CRBSIs can lead to increased costs associated with extended hospital stays, illness and death.
One of the major risk factors contributing to CRBSIs is skin organisms (flora) at the catheter insertion site.6 The CDC recommends the use of products containing CHG as one of the top five performance strategies found to be successful in reducing CRBSIs.4
The Centers for Medicare and Medicaid Services (CMS) considers CRBSIs to be ‘Never Events’ which are defined as “adverse events that are serious, largely preventable, and of concern to both the public and health care providers for the purpose of public accountability.” Several states have enacted laws requiring the disclosure of Never Events at hospitals and various remunerative or punitive measures for such events. CMS no longer reimburses for hospital-acquired CRBSIs, and other Never Events, and many private insurers are now following suit. Increasing media attention to hospital infections has raised public awareness of CRBSIs.
Learn more about CRBSIs, infection prevention, and 3M Health Care’s role in helping to minimize infection:
† in vivo on healthy adult subjects
*3M™ Tegaderm™ CHG Dressings have not been studied in a randomized clinical study as to their effectiveness in preventing CRBSIs.
BIOPATCH® is a registered trademark of ETHICON, INC.
1 Kluger DM, Maki DG. The relative risk of intravascular device related bloodstream infections in adults [Abstract]. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: American Society for Microbiology, 1999:514.
2 Rello J, Ochagavia A, Sabanes E, et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med 2000;162:1027--30.
3 Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg. 2001;136:229–34.
4 CDC. Guidelines for the prevention of intravascular catheter-related infections. MMWR 2002;51(No. RR-10).
5 Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted central venous
catheters used in hospitalized patients. Chest 2005;128(2):489-95.
Live Chat
GPO Contracts
Tegaderm™ CHG Dressings are on all six major GPOs including Amerinet, Broadlane, HPG, MedAssets, Novation and Premier.
How to Buy
To order Tegaderm™ CHG Dressings for your facility, contact your 3M Health Care Representative, click on the Live Chat icon above, call the 3M Health Care Customer Hotline at 1-800-228-3957, or find a in the U.S.
